Progression of corpus callosum atrophy in Alzheimer disease

Stefan J. Teipel, Wolfram Bayer, Gene E. Alexander, York Zebuhr, Diane Teichberg, Luka Kulic, Marc B. Schapiro, Hans Jürgen Möller, Stanley I. Rapoport, Harald Hampel

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Background: Atrophy of the corpus callosum in the absence of primary white matter degeneration reflects loss of intracortical projecting neocortical pyramidal neurons in Alzheimer disease (AD). Objectives: To determine individual rates of atrophy progression of the corpus callosum in patients with AD and to correlate rates of atrophy progression with clinical disease severity and subcortical disease. Methods: Magnetic resonance imaging-derived measurements of corpus callosum size were studied longitudinally in 21 patients clinically diagnosed as having AD (mean observation time, 17.0 ± 8.5 months) and 10 age-and sex-matched healthy controls (mean observation time, 24.1 ± 6.8 months). Results: Corpus callosum size was significantly reduced in AD patients at baseline. Annual rates of atrophy of total corpus callosum, splenium, and rostrum were significantly larger in AD patients (-7.7%, -12.1%, and -7.3%, respectively) than in controls (-0.9%, -1.5%, and 0.6%, respectively). Rates of atrophy of the corpus callosum splenium were correlated with progression of dementia severity in AD patients (p = 0.52, P<.02). The load of subcortical lesions at baseline (P<.05) predicted rate of anterior corpus callosum atrophy in healthy controls. Rates of atrophy of corpus callosum areas were independent of white matter hyperintensity load in patients with AD. Conclusions: Measurement of corpus callosum size allows in vivo mapping of neocortical neurodegeneration in AD over a wide range of clinical dementia severities and may be used as a surrogate marker for evaluation of drug efficacy.

Original languageEnglish (US)
Pages (from-to)243-248
Number of pages6
JournalArchives of Neurology
Volume59
Issue number2
StatePublished - 2002

Fingerprint

Corpus Callosum
Atrophy
Alzheimer Disease
Dementia
Observation
Agenesis of Corpus Callosum
Drug Evaluation
Alzheimer's Disease
Progression
Pyramidal Cells
Biomarkers
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Teipel, S. J., Bayer, W., Alexander, G. E., Zebuhr, Y., Teichberg, D., Kulic, L., ... Hampel, H. (2002). Progression of corpus callosum atrophy in Alzheimer disease. Archives of Neurology, 59(2), 243-248.

Progression of corpus callosum atrophy in Alzheimer disease. / Teipel, Stefan J.; Bayer, Wolfram; Alexander, Gene E.; Zebuhr, York; Teichberg, Diane; Kulic, Luka; Schapiro, Marc B.; Möller, Hans Jürgen; Rapoport, Stanley I.; Hampel, Harald.

In: Archives of Neurology, Vol. 59, No. 2, 2002, p. 243-248.

Research output: Contribution to journalArticle

Teipel, SJ, Bayer, W, Alexander, GE, Zebuhr, Y, Teichberg, D, Kulic, L, Schapiro, MB, Möller, HJ, Rapoport, SI & Hampel, H 2002, 'Progression of corpus callosum atrophy in Alzheimer disease', Archives of Neurology, vol. 59, no. 2, pp. 243-248.
Teipel SJ, Bayer W, Alexander GE, Zebuhr Y, Teichberg D, Kulic L et al. Progression of corpus callosum atrophy in Alzheimer disease. Archives of Neurology. 2002;59(2):243-248.
Teipel, Stefan J. ; Bayer, Wolfram ; Alexander, Gene E. ; Zebuhr, York ; Teichberg, Diane ; Kulic, Luka ; Schapiro, Marc B. ; Möller, Hans Jürgen ; Rapoport, Stanley I. ; Hampel, Harald. / Progression of corpus callosum atrophy in Alzheimer disease. In: Archives of Neurology. 2002 ; Vol. 59, No. 2. pp. 243-248.
@article{34bc415a142a447c876baf9bc2c389d6,
title = "Progression of corpus callosum atrophy in Alzheimer disease",
abstract = "Background: Atrophy of the corpus callosum in the absence of primary white matter degeneration reflects loss of intracortical projecting neocortical pyramidal neurons in Alzheimer disease (AD). Objectives: To determine individual rates of atrophy progression of the corpus callosum in patients with AD and to correlate rates of atrophy progression with clinical disease severity and subcortical disease. Methods: Magnetic resonance imaging-derived measurements of corpus callosum size were studied longitudinally in 21 patients clinically diagnosed as having AD (mean observation time, 17.0 ± 8.5 months) and 10 age-and sex-matched healthy controls (mean observation time, 24.1 ± 6.8 months). Results: Corpus callosum size was significantly reduced in AD patients at baseline. Annual rates of atrophy of total corpus callosum, splenium, and rostrum were significantly larger in AD patients (-7.7{\%}, -12.1{\%}, and -7.3{\%}, respectively) than in controls (-0.9{\%}, -1.5{\%}, and 0.6{\%}, respectively). Rates of atrophy of the corpus callosum splenium were correlated with progression of dementia severity in AD patients (p = 0.52, P<.02). The load of subcortical lesions at baseline (P<.05) predicted rate of anterior corpus callosum atrophy in healthy controls. Rates of atrophy of corpus callosum areas were independent of white matter hyperintensity load in patients with AD. Conclusions: Measurement of corpus callosum size allows in vivo mapping of neocortical neurodegeneration in AD over a wide range of clinical dementia severities and may be used as a surrogate marker for evaluation of drug efficacy.",
author = "Teipel, {Stefan J.} and Wolfram Bayer and Alexander, {Gene E.} and York Zebuhr and Diane Teichberg and Luka Kulic and Schapiro, {Marc B.} and M{\"o}ller, {Hans J{\"u}rgen} and Rapoport, {Stanley I.} and Harald Hampel",
year = "2002",
language = "English (US)",
volume = "59",
pages = "243--248",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Progression of corpus callosum atrophy in Alzheimer disease

AU - Teipel, Stefan J.

AU - Bayer, Wolfram

AU - Alexander, Gene E.

AU - Zebuhr, York

AU - Teichberg, Diane

AU - Kulic, Luka

AU - Schapiro, Marc B.

AU - Möller, Hans Jürgen

AU - Rapoport, Stanley I.

AU - Hampel, Harald

PY - 2002

Y1 - 2002

N2 - Background: Atrophy of the corpus callosum in the absence of primary white matter degeneration reflects loss of intracortical projecting neocortical pyramidal neurons in Alzheimer disease (AD). Objectives: To determine individual rates of atrophy progression of the corpus callosum in patients with AD and to correlate rates of atrophy progression with clinical disease severity and subcortical disease. Methods: Magnetic resonance imaging-derived measurements of corpus callosum size were studied longitudinally in 21 patients clinically diagnosed as having AD (mean observation time, 17.0 ± 8.5 months) and 10 age-and sex-matched healthy controls (mean observation time, 24.1 ± 6.8 months). Results: Corpus callosum size was significantly reduced in AD patients at baseline. Annual rates of atrophy of total corpus callosum, splenium, and rostrum were significantly larger in AD patients (-7.7%, -12.1%, and -7.3%, respectively) than in controls (-0.9%, -1.5%, and 0.6%, respectively). Rates of atrophy of the corpus callosum splenium were correlated with progression of dementia severity in AD patients (p = 0.52, P<.02). The load of subcortical lesions at baseline (P<.05) predicted rate of anterior corpus callosum atrophy in healthy controls. Rates of atrophy of corpus callosum areas were independent of white matter hyperintensity load in patients with AD. Conclusions: Measurement of corpus callosum size allows in vivo mapping of neocortical neurodegeneration in AD over a wide range of clinical dementia severities and may be used as a surrogate marker for evaluation of drug efficacy.

AB - Background: Atrophy of the corpus callosum in the absence of primary white matter degeneration reflects loss of intracortical projecting neocortical pyramidal neurons in Alzheimer disease (AD). Objectives: To determine individual rates of atrophy progression of the corpus callosum in patients with AD and to correlate rates of atrophy progression with clinical disease severity and subcortical disease. Methods: Magnetic resonance imaging-derived measurements of corpus callosum size were studied longitudinally in 21 patients clinically diagnosed as having AD (mean observation time, 17.0 ± 8.5 months) and 10 age-and sex-matched healthy controls (mean observation time, 24.1 ± 6.8 months). Results: Corpus callosum size was significantly reduced in AD patients at baseline. Annual rates of atrophy of total corpus callosum, splenium, and rostrum were significantly larger in AD patients (-7.7%, -12.1%, and -7.3%, respectively) than in controls (-0.9%, -1.5%, and 0.6%, respectively). Rates of atrophy of the corpus callosum splenium were correlated with progression of dementia severity in AD patients (p = 0.52, P<.02). The load of subcortical lesions at baseline (P<.05) predicted rate of anterior corpus callosum atrophy in healthy controls. Rates of atrophy of corpus callosum areas were independent of white matter hyperintensity load in patients with AD. Conclusions: Measurement of corpus callosum size allows in vivo mapping of neocortical neurodegeneration in AD over a wide range of clinical dementia severities and may be used as a surrogate marker for evaluation of drug efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0036129788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036129788&partnerID=8YFLogxK

M3 - Article

C2 - 11843695

AN - SCOPUS:0036129788

VL - 59

SP - 243

EP - 248

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 2

ER -